SoP LibraryAnosmia

Statement of Principles

Anosmia — DVA SoP factors

Every factor in the Repatriation Medical Authority Statements of Principles for Anosmia. DVA can only accept a claim for Anosmia if at least one of these factors is met and connected to your service. Reasonable Hypothesis (RH) applies to operational service; Balance of Probabilities (BoP) applies to peacetime service.

Source: Repatriation Medical Authority Statements of Principles as held by the Veterans Health Centre. SoPs are amended and replaced regularly; always confirm the current instrument at rma.gov.au before relying on it.

Anosmia

RH No. 19 of 2021 · BoP No. 20 of 202142 factors

Meaning of anosmia: For the purposes of this Statement of Principles, anosmia means an acquired, total and permanent loss of the ability to smell, due to a defect in the olfactory neuroepithelium, olfactory nerves or olfactory neural pathways in the brain.

Reasonable Hypothesis (RH) — Statement of Principles No. 19 of 2021

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting anosmia or death from anosmia with the circumstances of a person's relevant service:

  1. (1)
    having sinusitis for at least the two years before the clinical onset of anosmia;
  2. (2)
    having perennial allergic rhinitis for at least the two years before the clinical onset of anosmia;

    Note: perennial allergic rhinitis is defined in the Schedule 1 - Dictionary.

  3. (3)
    having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of anosmia;

    Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.

  4. (4)
    having sarcoidosis at the time of the clinical onset of anosmia;
  5. (5)
    having Paget's disease of bone affecting the skull at the time of the clinical onset of anosmia;
  6. (6)
    having a neurological disease from the specified list of neurological diseases at the time of the clinical onset of anosmia;

    Note: specified list of neurological diseases is defined in the Schedule 1 - Dictionary.

  7. (7)
    having hepatic encephalopathy at the time of the clinical onset of anosmia;
  8. (8)
    having chronic renal failure at the time of the clinical onset of anosmia;

    Note: chronic renal failure is defined in the Schedule 1 - Dictionary.

  9. (9)
    having diabetes mellitus before the clinical onset of anosmia;
  10. (10)
    having a disorder of mental health from the specified list of disorders of mental health at the time of the clinical onset of anosmia;

    Note: specified list of disorders of mental health is defined in the Schedule 1 - Dictionary.

  11. (11)
    having a condition or procedure from the specified list of conditions and procedures, which damages the olfactory neuroepithelium, the olfactory bulb or the olfactory neural pathways in the brain at the time of the clinical onset of anosmia;

    Note: specified list of conditions and procedures is defined in the Schedule 1 - Dictionary.

  12. (12)
    being treated with a drug which is associated in the individual with: (a) the development of anosmia within three weeks of commencing drug therapy, in the absence of clinical or laboratory evidence of anosmia prior to commencing drug therapy; and (b) the persistence of anosmia after discontinuing drug therapy;
  13. (13)
    undergoing a course of therapeutic radiation for cancer, where the olfactory neuroepithelium, olfactory bulb, or olfactory neural pathways in the brain were in the field of radiation, within the 30 days before the clinical onset of anosmia;
  14. (14)
    receiving an intranasal application of a preparation containing zinc gluconate or zinc sulphate within the 48 hours before the clinical onset of anosmia;
  15. (15)
    taking intranasal cocaine such that there is destruction of the nasal septum, palate or paranasal sinuses before the clinical onset of anosmia;
  16. (16)
    inhaling fumes from a metal from the specified list of metals, or a compound containing a metal from the specified list of metals, for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased, the clinical onset of anosmia has occurred within one year of cessation;

    Note: fumes and specified list of metals are defined in the Schedule 1 - Dictionary.

  17. (17)
    inhaling fumes from a volatile substance from the specified list of volatile substances for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased, the clinical onset of anosmia has occurred within one year of cessation;

    Note: fumes and specified list of volatile substances are defined in the Schedule 1 - Dictionary.

  18. (18)
    experiencing acute, symptomatic poisoning from a neurotoxic substance from the specified list of neurotoxic substances within the 30 days before the clinical onset of anosmia;

    Note: specified list of neurotoxic substances is defined in the Schedule 1 - Dictionary.

  19. (19)
    where smoking has not ceased prior to the clinical onset of anosmia, having smoked at least 20 pack-years of tobacco products before the clinical onset of anosmia;

    Note: pack-year of tobacco products is defined in the Schedule 1 - Dictionary.

  20. (20)
    having pellagra at the time of the clinical onset of anosmia;

    Note: pellagra is defined in the Schedule 1 - Dictionary.

  21. (21)
    having vitamin B12 deficiency at the time of the clinical onset of anosmia;
  22. (22)
    having envenomation by the Australian mulga snake (Pseudoechis australis) or the South African Berg adder (Bitis atropos) at the time of the clinical onset of anosmia;

Balance of Probabilities (BoP) — Statement of Principles No. 20 of 2021

20 factors

At least one of the following factors must exist before it can be said that, on the balance of probabilities, anosmia or death from anosmia is connected with the circumstances of a person's relevant service:

  1. (1)
    having sinusitis for at least the five years before the clinical onset of anosmia;
  2. (2)
    having perennial allergic rhinitis for at least the five years before the clinical onset of anosmia;

    Note: perennial allergic rhinitis is defined in the Schedule 1 - Dictionary.

  3. (3)
    having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of anosmia;

    Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.

  4. (4)
    having sarcoidosis at the time of the clinical onset of anosmia;
  5. (5)
    having Paget's disease of bone affecting the skull at the time of the clinical onset of anosmia;
  6. (6)
    having a neurological disease from the specified list of neurological diseases at the time of the clinical onset of anosmia;

    Note: specified list of neurological diseases is defined in the Schedule 1 - Dictionary.

  7. (7)
    having hepatic encephalopathy at the time of the clinical onset of anosmia;
  8. (8)
    having chronic renal failure at the time of the clinical onset of anosmia;

    Note: chronic renal failure is defined in the Schedule 1 - Dictionary.

  9. (9)
    having alcohol-induced major neurocognitive disorder, amnestic- confabulatory type, persistent or alcohol use disorder at the time of the clinical onset of anosmia;
  10. (10)
    having a condition or procedure from the specified list of conditions and procedures, which damages the olfactory neuroepithelium, the olfactory bulb or the olfactory neural pathways in the brain at the time of the clinical onset of anosmia;

    Note: specified list of conditions and procedures is defined in the Schedule 1 - Dictionary.

  11. (11)
    being treated with a drug which is associated in the individual with: (a) the development of anosmia within three weeks of commencing drug therapy, in the absence of clinical or laboratory evidence of anosmia prior to commencing drug therapy; and (b) the persistence of anosmia after discontinuing drug therapy;
  12. (12)
    undergoing a course of therapeutic radiation for cancer, where the olfactory neuroepithelium, olfactory bulb, or olfactory neural pathways in the brain were in the field of radiation, within the 30 days before the clinical onset of anosmia;
  13. (13)
    receiving an intranasal application of a preparation containing zinc gluconate or zinc sulphate within the 48 hours before the clinical onset of anosmia;
  14. (14)
    taking intranasal cocaine such that there is destruction of the nasal septum, palate or paranasal sinuses before the clinical onset of anosmia;
  15. (15)
    inhaling fumes from cadmium or nickel for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased, the clinical onset of anosmia has occurred within one year of cessation;

    Note: fumes is defined in the Schedule 1 - Dictionary.

  16. (16)
    inhaling fumes from acrylate or methylacrylate for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased, the clinical onset of anosmia has occurred within one year of cessation;

    Note: fumes is defined in the Schedule 1 - Dictionary.

  17. (17)
    experiencing acute, symptomatic poisoning from a neurotoxic substance from the specified list of neurotoxic substances within the 30 days before the clinical onset of anosmia;

    Note: specified list of neurotoxic substances is defined in the Schedule 1 - Dictionary.

  18. (18)
    where smoking has not ceased prior to the clinical onset of anosmia, having smoked at least 20 pack-years of tobacco products before the clinical onset of anosmia;

    Note: pack-year of tobacco products is defined in the Schedule 1 - Dictionary.

  19. (19)
    having vitamin B12 deficiency at the time of the clinical onset of anosmia;
  20. (20)
    having envenomation by the Australian mulga snake (Pseudoechis australis) or the South African Berg adder (Bitis atropos) at the time of the clinical onset of anosmia;

A VHC Diagnostic Assessment addresses each of these factors one by one against your service record and clinical history. See how a VHC DVA claim works, see all fees ($600 + GST per stage) or book an appointment.

About Dr Thomas Perkins

One doctor. Every report.

Founding doctor of the Veterans Health Centre in Ipswich, Queensland, and one of Australia's most experienced practitioners in veterans' medicolegal medicine.

Dr Perkins has spent more than thirteen years working exclusively with current and former ADF members — treating their conditions, writing their reports and navigating the DVA system alongside them. With over 100,000 claims submitted and 2,000 Permanent Impairment Assessments completed, he has seen precisely what separates an accepted claim from a rejected one at every level, from initial liability to the Veterans' Review Board.

Every chart review, diagnostic assessment, impairment rating and appeal that leaves this clinic is personally overseen by Dr Perkins. No template, no locum, no hand-off.

0429 146 039 reception@vhc.org.au

Book appointment